LTS Lohmann Therapie-Systeme AG Sustainability Profile
LTS Lohmann Therapie-Systeme AG, commonly referred to as LTS, is a leading global player in the pharmaceutical and medical device industry, headquartered in Andernach, Germany. Founded in 1981, the company has established itself as a pioneer in transdermal drug delivery systems, offering innovative solutions that enhance patient compliance and therapeutic efficacy. With a strong presence in Europe, North America, and Asia, LTS focuses on the development and manufacturing of advanced drug delivery technologies, including patches and films. Their unique approach combines cutting-edge research with state-of-the-art production capabilities, ensuring high-quality products tailored to meet diverse medical needs. Recognised for its commitment to excellence, LTS has achieved significant milestones, solidifying its market position as a trusted partner for pharmaceutical companies worldwide.
DitchCarbon Score
How does LTS Lohmann Therapie-Systeme AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
LTS Lohmann Therapie-Systeme AG's score of 40 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
LTS Lohmann Therapie-Systeme AG's reported carbon emissions
LTS Lohmann Therapie-Systeme AG, headquartered in Germany, has set ambitious climate commitments to address its carbon emissions. Although specific emissions data for the most recent year is not available, the company has established significant reduction targets. LTS Lohmann Therapie-Systeme AG commits to reducing its absolute Scope 1 greenhouse gas (GHG) emissions by 50% by 2030 and by 90% by 2050, using 2023 as the base year. Similarly, the company aims to achieve a 50% reduction in absolute Scope 2 GHG emissions by 2030 and a 90% reduction by 2050. Furthermore, LTS has set a target to reduce absolute Scope 3 GHG emissions by 25% by 2030 and by 90% by 2050. In addition to these targets, LTS Lohmann Therapie-Systeme AG has pledged to reach net-zero GHG emissions across its entire value chain by 2050. These commitments align with the Science Based Targets initiative (SBTi) and are classified under the 1.5°C target framework, demonstrating the company's dedication to mitigating climate change impacts. Overall, LTS Lohmann Therapie-Systeme AG is taking proactive steps to significantly reduce its carbon footprint and contribute to global climate goals.
How Carbon Intensive is LTS Lohmann Therapie-Systeme AG's Industry?
How Carbon Intensive is LTS Lohmann Therapie-Systeme AG's Location?
LTS Lohmann Therapie-Systeme AG's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
LTS Lohmann Therapie-Systeme AG has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
